Made-to-Order Contact Lenses Now Ship to U.S. and Canadian
Customers in Approximately One Week
SAN RAMON, Calif., March 27, 2023— CooperVision has accelerated North American delivery times by more than 50% of all Biofinity® toric multifocal contact lenses for U.S. and Canadian customers after transitioning the manufacturing to its New York production facility in late 2022. All trial lenses and six-packs of the made-to-order lenses now originate from CooperVision’s technologically advanced facility in Scottsville, N.Y., reaching customers in seven days, on average.
To ensure that eye care professionals (ECPs) can provide a lens to meet the unique needs of every patient, Biofinity® toric multifocal lenses are available in more than 200,000 unique prescription options.1
“CooperVision’s made-to-order advantage enables us to offer highly customized contact lenses in very little time,” said Doug Brayer, Director of Marketing, Frequent Replacement Brands, CooperVision. “By moving Biofinity® toric multifocal production from the U.K. to the U.S. for our North American customers, we make and deliver these sophisticated lenses to our customers and their patients even faster—with most orders shipping in just a few days.”
“The faster, consistent Biofinity toric multifocal delivery times have made a huge difference for our practice. We are able to schedule patients for follow-up appointments in a more timely fashion, and if we need to adjust the prescription, the patient isn't waiting weeks for new trials,” said Aaron Stewart, OD, who practices at PersonalEYES Vision Care in Grand Rapids, Mich. “As a result, we are prescribing the product much more frequently, and seeing great success with it.”
CooperVision Biofinity® toric multifocal combines the comfort and proven optical designs of Biofinity® toric2—the most prescribed toric lens on the market3 and Biofinity® multifocal. Like all Biofinity® silicone hydrogel lenses, Biofinity® toric multifocal features CooperVision’s Aquaform® Technology, which offers superb breathability and higher moisture content to keep eyes comfortable and healthy.4*
Biofinity® toric multifocal orders for other markets continue to be manufactured at CooperVision’s U.K. facility.
# # #
1 CVI data on file, 2019. Based on total number of prescription option combinations (for sphere, cylinder, axis and add - including D & N combinations) manufactured.
2 CVI Biofinity toric multifocal lenses combine the comfort, proven optical designs and trusted technology of Biofinity toric and Biofinity multifocal contact lenses.
3 CVI Biofinity toric multifocal lenses combine the comfort, proven optical designs and trusted technology of Biofinity toric and Biofinity multifocal contact lenses.
4 Aquaform Technology, a CooperVision technological breakthrough, allows <Biofinity / MyDay> lenses to have superb breathability, combined with higher moisture content. This keeps you comfortable and your eyes clear, white and healthy. What's more, all <Biofinity / MyDay> lenses have a smooth, naturally wettable lens surface that resists deposits, so you get incredible comfort and clarity that lasts all day. FOOTNOTE: *During daily wear.
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies, and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Media Contact
Heather Kowalczyk, APR, McDougall Communications for CooperVision
heather@mcdougallpr.com or (585) 434-2148